We are very happy to share with you about HCS and 3D in vitro models thanks to a labroots.com webinar on October 27, 2019!

This webinar is made with our partner Molecular Devices and it will present you many tips on how to handle 3D cell culture systems such as the BIOMIMESYS hydroscaffold on high-content imagers.


3D cell culture systems have recently emerged as tools for reproducing the cellular environment and the organization of tissues/organs, where cells are connected to each other and to the surrounding extracellular matrix (ECM).  Join us for this webinar with HCS Pharma, a biotechnology start-up company based in France, as we discuss the biological characterization of cells in 3D matrices for liver, brain and adipose tissues, and cancer modeling, using BIOMIMESYS® hydroscaffold technology. We will also discuss high-content screening solutions for examining 3D in vitro models.

In this webinar, you will learn from Dr. Zied Souguir, inventor of the BIOMIMESYS® hydroscaffold, about the unique differentiation of this technology and its application for high-throughput drug screening.  Dr. Elodie Vandenhaute, a 3D cell culture expert at HCS Pharma, will demonstrate how to handle 3D cell culture systems such as the BIOMIMESYS hydroscaffold on high-content imagers, and how these can be integrated into HCS platforms in high throughput, such as HCS Pharma’s HAPIx platform. Finally, Daniel O’Connor, Drug Discovery Director (Molecular Devices) will discuss new High-Content Screening (HCS) technologies that are enabling researchers to capture more data at greater depths for 3D and thick tissue samples.

BIOMIMESYS® hydroscaffold technology mimics the native ECM and allows the culture of cells in a physiologically-relevant 3D cell culture system. It is based on hyaluronic acid, a major component of ECM currently under-represented in cell culture systems, and biofunctionalized with other ECM components according to the organ/tissue of interest. This matrix is provided in cell culture plates in a ready-to-use format and is compatible with all common downstream analytical techniques. It can be used to great benefit in early drug discovery as it is adapted to HCS, ADME-Tox profiling, and disease modeling. 

Grégory MAUBON

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created www.augmented-reality.fr and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.